A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases

Cancer

Volumn 97, Issue 12, 2003, Pages 2988-2994

  Pagliaro, Lance C ^a   Delpassand, Ebrahim S ^a   Williams, Dallas ^a   Millikan, Randall E ^a   Tu, Shi Ming ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone targeted therapy; Gemcitabine; Metastatic prostate carcinoma; Phase I clinical trial; Phase II clinical trial; Strontium 89

Indexed keywords

ANDROGEN; GEMCITABINE; PROSTATE SPECIFIC ANTIGEN; STRONTIUM 89;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FEVER; FATIGUE; GRANULOCYTE; HUMAN; INFECTION; MALE; MAXIMUM TOLERATED DOSE; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CARCINOMA; RASH; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

AGED; BONE NEOPLASMS; CARCINOMA; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; STRONTIUM; STRONTIUM RADIOISOTOPES; TESTOSTERONE;

EID: 0037672705     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11412     Document Type: Article

References (28)

1. McRea LE, Karafin L. Carcinoma of the prostate: metastases, therapy, and survival - a statistical analysis of 500 cases. Int Coll Surg J. 1958;29:49-63.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
3. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
4. Robinson RG, Blake GM, Preston DF, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics. 1989;9:271-281.
5. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a Phase I/II trial. J Nucl Med. 1993;34:1839-1844.
6. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
7. Millikan R, Baez L, Banerjee T, et al. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol. 2001;6: 111-115.
8. Tu SM, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol. 1996;2:191-197.
9. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized Phase II trial. Lancet. 2001;357:336-341.
10. Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood. 1997;90:270-278.
11. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23(Suppl 10):3-15.
12. Morant R, Bernhard J, Maibach R, et al. Response and palliation in a Phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2000;11:183-188.
13. Simon R. How large should a Phase II trial be? Cancer Treat Rep. 1987;71:1079-1085.
14. Ben-Josef E, Porter AT. Radioisotopes in the treatment of bone metastases. Ann Med. 1997;29:31-35.
15. Pecher C. Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in treatment of metastatic bone cancer. Univ Calif Publ Pharmacol. 1942;11:117-149.
16. Mertens WC, Porter AT, Reid RH, Powe JE. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med. 1992;33:1437-1443.
17. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79-86.
18. Torti FM, Aston D, Lum BL, et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol. 1983;1:477-482.
19. Ellerhorst JA, Tu SM, Amato RJ, et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res. 1997;3:2371-2376.
20. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol. 1999;17:1664-1671.
21. Petrylak DP, Macarthur R, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958-967.
22. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
23. Rini BI, Vogelzang NJ, Dumas MC, Wade JL, Taber D, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419-2426.
24. Awada A, Biganzoli L, Cufer T, et al. An EORTC-IDBBC Phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. Eur J Cancer. 2002;38:773-778.
25. Schulz L, Schalhorn A, Wilmanns W, Heinemann V. Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells [abstract]. Proc Am Soc Clin Oncol. 1998;17: 251a.
26. Ren Q, Kao V, Grem JL. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2′-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res. 1998;4:2811-2818.
27. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998;16:2977-2985.
28. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002;20:582-587.